Mitra Devarati, Catalano Paul J, Cimbak Nicole, Damato Antonio L, Muto Michael G, Viswanathan Akila N
Department of Radiation Oncology, Dana-Farber Cancer Institute and Brigham & Women's Hospital, Boston, MA, USA.
Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA, USA.
J Gynecol Oncol. 2016 Jan;27(1):e4. doi: 10.3802/jgo.2016.27.e4. Epub 2015 Oct 8.
Lower extremity lymphedema adversely affects quality of life by causing discomfort, impaired mobility and increased risk of infection. The goal of this study is to investigate factors that influence the likelihood of lymphedema in patients with endometrial cancer who undergo adjuvant radiation with or without chemotherapy.
A retrospective chart review identified all stage I-III endometrial cancer patients who had a hysterectomy with or without complete staging lymphadenectomy and adjuvant radiation therapy between January 2006 and February 2013. Patients with new-onset lymphedema after treatment were identified. Logistic regression was used to find factors that influenced lymphedema risk.
Of 212 patients who met inclusion criteria, 15 patients (7.1%) developed new-onset lymphedema. Lymphedema was associated with lymph-node dissection (odds ratio [OR], 5.6; 95% CI, 1.01 to 105.5; p=0.048) and with the presence of pathologically positive lymph nodes (OR, 4.1; 95% CI, 1.4 to 12.3; p=0.01). Multivariate logistic regression confirmed the association with lymph-node positivity (OR, 3.2; 95% CI, 1.0007 to 10.7; p=0.0499) when controlled for lymph-node dissection. Median time to lymphedema onset was 8 months (range, 1 to 58 months) with resolution or improvement in eight patients (53.3%) after a median of 10 months.
Lymph-node positivity was associated with an increased risk of lymphedema in endometrial cancer patients who received adjuvant radiation. Future studies are needed to explore whether node-positive patients may benefit from early lymphedema-controlling interventions.
下肢淋巴水肿会导致不适、行动不便并增加感染风险,从而对生活质量产生不利影响。本研究的目的是调查在接受辅助放疗(无论是否联合化疗)的子宫内膜癌患者中,影响淋巴水肿发生可能性的因素。
通过回顾性病历审查,确定了2006年1月至2013年2月期间所有接受子宫切除术(无论是否进行完整分期淋巴结清扫)及辅助放疗的Ⅰ-Ⅲ期子宫内膜癌患者。识别出治疗后新发淋巴水肿的患者。采用逻辑回归分析来找出影响淋巴水肿风险的因素。
在符合纳入标准的212例患者中,15例(7.1%)出现新发淋巴水肿。淋巴水肿与淋巴结清扫相关(比值比[OR],5.6;95%置信区间[CI],1.01至105.5;p = 0.048),与病理检查阳性淋巴结的存在也相关(OR,4.1;95% CI,1.4至12.3;p = 0.01)。多因素逻辑回归分析在控制淋巴结清扫因素后,证实了与淋巴结阳性的相关性(OR,3.2;95% CI,1.0007至10.7;p = 0.0499)。淋巴水肿开始出现的中位时间为8个月(范围,1至58个月),8例患者(53.3%)在中位时间10个月后症状缓解或改善。
在接受辅助放疗的子宫内膜癌患者中,淋巴结阳性与淋巴水肿风险增加相关。未来需要开展研究,以探索淋巴结阳性患者是否可能从早期淋巴水肿控制干预措施中获益。